Q4 2022 Nordic Nanovector ASA Earnings Call Transcript
Good morning, everyone, and thank you for joining this 2022 presentation. I'm Ludvik Sandnes, and I will, on behalf of the former Board of Directors and the CEO explain what happened last year. They had a very active year with 27 Board meetings. And my presentation will be recorded, so I therefore take questions at the end. And I hope the details given in this presentation will answer most of the questions you might have.
As an update, last year became an annus horribilis for Nordic Nanovector. Betalutin/PARADIGME had to be discontinued, as you know, due to continued severe difficulties in the enrolling of patients, the impact of COVID-19 as for many other studies, disappointing regulatory feasibility, evaluation and poor efficacy data; below threshold values set for the study and noncompetitive profile in the crowded market going forward. Independent review concluded that the efficacy data would not give Betalutin a competitive profile in third-line follicular lymphoma. The company restructure was initiated in the second half and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
